NEW YORK (GenomeWeb) – Biocept plans to offer about $15 million of its common stock in a public offering, the firm said in documents filed with the US Securities and Exchange Commission on Wednesday. 

The company has not priced its offering, but said that it plans to offer about 6.3 million shares of its stock. Its shares closed at $2.52 in Wednesday trade on the Nasdaq. 

Aegis Capital and Feltl and Co. are listed as the underwriters on the offering. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.